Published: November 14, 2017
A new genetic test could help diagnose oesophageal cancer up to 8 years before symptoms appear in people at a high risk of the disease, according to new research presented at the National Cancer Research Institute’s (NCRI) Cancer Conference in Liverpool this week.
Published: November 09, 2017
Rebecca Fitzgerald's lab received press coverage in both the Telegraph and the Times following the 2017 NCRI conference. The articles focus on the group's development of the Cytosponge, an innovative and non-invasive test to detect pre-cancerous changes in the oesophagus.
Published: November 03, 2017
Now in its fifth year, BioBeat is a collaborative innovation platform for business entrepreneurs and leaders in bioscience. BioBeat’s Movers and Shakers annual report demonstrates how talented women in biobusiness are driving innovation in life science. This year the report recognises 50 outstanding women leaders across five key translational themes: Great Science, Financial Enablers, Collaboration, Patient Impact, and Infrastructure Innovation. Rebecca is recognised in the report’s Great Science theme which features women who have been making great scientific advances towards giving us a healthier world. Read more
Published: September 27, 2017
We are delighted to announce two calls for pump priming funding from the CRUK Cambridge Centre Early Detection Programme. The aim of these schemes is to fund early-stage research projects into early detection.
Published: August 23, 2017
The new CRUK Early Detection Funding awards are now open for application.
Published: July 18, 2017
This recent debate was attended by Programme Lead Prof Rebecca Fitzgerald.
Published: July 12, 2017
I'm running the Cambridge 10km Race for Life again this year. Those who know me will also know how much I dislike running, which I hope gives you all the more reason to sponsor me. I’ve been working hard in training and am trying to improve my time from 2015 (56 minutes), running with my dog for extra motivation. I made it 9.5km in 54 minutes last weekend so now I am on to the final push.
Please consider supporting me and contributing towards the vital research that CRUK are supporting every day across the world, and particular here at home in the Early Detection Programme. Every donation really makes a huge difference to CRUK. My fundraising page is https://fundraise.cancerresearchuk.org/page/sarahs-fundraising-page-6887
Published: July 12, 2017
We are delighted to announce that Dr Daniel Muñoz-Espín, Group Leader for the CRUK Cambridge Centre Early Detection Programme, has been awarded a £850 000 New Investigator Research Grant (NIRG) by the MRC. This competitive award is aimed at researchers who are in the process of becoming independent Principal Investigators. The award will support Daniel’s research work on cellular plasticity and senescence at the origin of lung cancer and will enable him to recruit a new member of staff to his group.
Daniel says “This is a great boost to my research and I am extremely pleased that the MRC have chosen to invest in my work. n the long term, I hope my work increases our understanding of the fundamental mechanisms and processes that contribute to the initiation and progression of lung cancer. At present, and in most of the cases, the cell of origin of lung cancer remains largely unknown. Such knowledge is crucial to develop more efficient methods to detect lung cancer earlier and to implement more efficient therapeutic interventions”.
Please join us in congratulating Daniel in gaining this prestigious award.
Published: July 11, 2017
SCIENTISTS in Cambridge are to run a PAN cancer clinical trial to see if breath samples can be used to detect cancer in its early stages, the Cancer Research UK (CRUK) Cambridge Centre and Owlstone Medical announced on 10 July, 2017.
The large scale clinical trial will be carried out by researchers at the CRUK Cambridge Centre, the University of Cambridge and Cambridge University Hospitals NHS Foundation Trust in collaboration with diagnostics company, Owlstone Medical.
Published: June 20, 2017
A large scale study of women carrying faults in important cancer genes should enable doctors to provide better advice and counselling for treatments and lifestyle changes aimed at reducing this risk, suggests a new study published today.
“The results show clearly and for the first time in a prospective study, that the cancer risks for women with faults in BRCA1 and BRCA2 depend both on the precise mutation and the woman’s family cancer history,” - Doug Easton